COMP <GO>
SHC vs JNJ // REVENUE GROWTH (YOY)
Sotera Health Company (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SHC 1
— JNJ 11
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $18.15 (-2.94%) • MKT CAP: $5.34B
revenue-growth
5.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.50% | 67.90% | -12.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 25.50% | -22.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.5x | 18.5x | +15.00 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.80% | 2.97% | -0.17 | JNJ | /fcf-yield <GO> |
| Operating Margin | 8.20% | 34.70% | -26.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.70% | 28.50% | -21.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.70% | 6.00% | -0.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.56 | 5.59 | -4.03 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 60.4 | -12.41 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | SHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.7x | 23.0x | +40.70 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.34B | $662.49B | -$657.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SHC REV | JNJ REV | SHC GROSS % | JNJ GROSS % | SHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.16B | $94.19B | 55.5% | 67.9% | $149.2M | $19.70B |
| FY 2024 | $1.10B | $88.82B | 54.7% | 69.1% | $45.1M | $19.84B |
| FY 2023 | $1.05B | $85.16B | 44.0% | 44.0% | -$194.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SHC // BETA 1.10
JNJ // BETA 1.08